Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cystinosis].

H Watanabe1, S Kamoshita

  • 1Department of Glyco Cell Biology, Frontier Research Program, Riken.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|July 1, 1992
PubMed
Summary
This summary is machine-generated.

Cystinosis, a lysosomal transport disorder, involves cystine buildup. Early oral cysteamine therapy shows promise for improving symptoms and maintaining kidney function in affected infants.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Correlation between labeling index by proliferating cell nuclear antigen (PCNA) staining and growth rate in nude mice: preliminary report].

Nihon Geka Gakkai zasshi·1992
Same author

Immunohistochemical study of the histogenesis of esophageal carcinosarcoma.

Japanese journal of clinical oncology·1992
Same author

Decreased aortic compliance aggravates subendocardial ischaemia in dogs with stenosed coronary artery.

Cardiovascular research·1992
Same author

Immunohistochemical study of the sympathetic and sensory innervation to the blood vessels of the dog forepaw.

The Tohoku journal of experimental medicine·1992
Same author

[Human lung cancer cell lines in our laboratory: establishment of three large cell carcinoma cell lines and their biological characterization].

Human cell·1992
Same author

Ambulatory blood pressure and postprandial hypotension.

American heart journal·1992
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Area of Science:

  • Biochemistry
  • Genetics
  • Pediatrics

Context:

  • Cystinosis is a rare, autosomal recessive lysosomal storage disease.
  • It results from a defective lysosomal cystine transporter, leading to cystine accumulation.
  • This accumulation causes multi-organ damage, particularly in the kidneys.

Purpose:

  • To review the current understanding of cystinosis pathogenesis.
  • To discuss advancements in diagnosis and treatment strategies.
  • To highlight the potential of early therapeutic interventions.

Summary:

  • Cystinosis pathogenesis involves lysosomal cystine accumulation due to transport defects.
  • Renal transplantation is effective for end-stage renal failure but does not address systemic accumulation.

Related Experiment Videos

  • Oral cysteamine therapy facilitates cystine excretion and symptom improvement.

    • Impact:

    • Oral cysteamine offers a promising treatment for cystinosis, reducing cystine burden.
    • Early initiation of cysteamine therapy may preserve renal function and improve long-term outcomes.
    • Further research is exploring optimal timing for cysteamine treatment to maximize benefits.